Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study

被引:155
作者
Murtola, Teemu J. [1 ]
Tammela, Teuvo L. J.
Lahtela, Jorma
Auvinen, Anssi
机构
[1] Univ Tampere, Sch Publ Hlth, FIN-33014 Tampere, Finland
[2] Univ Tampere, Tampere Univ Hosp, Dept Urol, FIN-33014 Tampere, Finland
[3] Univ Tampere, Sch Med, FIN-33014 Tampere, Finland
[4] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland
[5] Finnish Canc Inst, Helsinki, Finland
关键词
D O I
10.1158/1055-9965.EPI-07-0599
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previous studies have shown that statin use may reduce prostate cancer risk. In the current study, we evaluated the association between serum cholesterol-lowering medication use and prostate cancer risk at the population level. Materials and Methods: All newly diagnosed prostate cancer cases in Finland during 1995 to 2002 and matched controls (24,723 case control pairs) were identified from the Finnish Cancer Registry and the Population Register Center, respectively. Detailed information on cholesterol-lowering drug purchases during the study period was obtained from the prescription database of the Social Insurance Institution of Finland. Results: After adjustment for potential confounders, having ever-use of any statin was associated with marginally elevated overall prostate cancer risk [odds ratio (OR), 1.07; 95% confidence interval (95% CI), 1.00-1.16]. However, none of the statins was associated with the overall prostate cancer risk when analyzed separately. On the other hand, the risk of advanced prostate cancer was decreased among users of atorvastatin, lovastatin, and simvastatin (OR 0.61, 95% CI 0.37-0.98; OR 0.61, 95% CI 0.43-0.85; and OR 0.78, 95% CI 0.61-1.01, respectively). The risk was not affected among users of other cholesterol drug groups. Conclusions: Our large population-based study showed no evidence for reduced overall prostate cancer risk among users of cholesterol-lowering drugs, whereas the risk of advanced cancer was decreased among statin users.
引用
收藏
页码:2226 / 2232
页数:7
相关论文
共 36 条
[1]   Relationship between obesity and prostate cancer [J].
Amling, CL .
CURRENT OPINION IN UROLOGY, 2005, 15 (03) :167-171
[2]  
[Anonymous], 2006, MED J AUSTRALIA
[3]  
[Anonymous], 2002, DRUG REIMBURSEMENT S
[4]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[5]   Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials [J].
Bonovas, Stefanos ;
Filioussi, Kalitsa ;
Tsavaris, Nikolaos ;
Sitaras, Nikolaos M. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4808-4817
[6]   Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer [J].
Bravi, F ;
Scotti, L ;
Bosetti, C ;
Talamini, R ;
Negri, E ;
Montella, M ;
Franceschi, S ;
La Vecchia, C .
ANNALS OF ONCOLOGY, 2006, 17 (06) :1014-1017
[7]   Statins and risk of cancer: A systematic review and metaanalysis [J].
Browning, Danielle R. L. ;
Martin, Richard M. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (04) :833-843
[8]   Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening [J].
Ciatto, S ;
Zappa, M ;
Villers, A ;
Paez, A ;
Otto, S ;
Auvinen, A .
BJU INTERNATIONAL, 2003, 92 :97-100
[9]   Statin use and the risk of breast and prostate cancer [J].
Coogan, PF ;
Rosenberg, L ;
Palmer, JR ;
Strom, BL ;
Zauber, AG ;
Shapiro, S .
EPIDEMIOLOGY, 2002, 13 (03) :262-267
[10]   Epidemiology of prostate cancer [J].
Crawford, ED .
UROLOGY, 2003, 62 (6A) :3-12